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Poland is widely known to be a region of low gastric cancer incidence. In 2011, 5368 people (3510 men and 1858 women) were diagnosed with malignant gastric cancer, accounting for 4.89% and 2.56%, respectively, of all malignant cancers of all organs. In the same year, 3478 men and 1761 women died of gastric cancer, resulting in a mortality of 6.75% and 4.33% considering all malignant cancers (1) . In general terms, both morbidity and mortality due to gastric cancer declined over the last 70 years (2) . Still, 880 thousand people were diagnosed with gastric cancer in 2000, of whom 650,000 died (3) .
Although gastric cancer is among the most common malignant cancers in Poland, most cases are diagnosed in advanced stages of the disease and only about 50-70% are eligible for surgery with the intention to treat: total or nearly total gastrectomy with the removal of regional lymph nodes (most commonly D2 lymphadenectomy).
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Gastrectomy with splenectomy in gastric cancer Surgical interventions are at the heart of treatment in patients with locally advanced gastric cancer and the choice of surgery depends on the clinical advancement (TNM), cancer type, malignancy grade and localisation. Endoscopic submucosal dissection is reserved for intestinal type cT1 sm 1 tumours (type I according to the Lauren classification), less than 3 cm in diameter. At this stage of advancement, the risk of metastasis to regional lymph nodes is estimated at less than 3%. In the remaining cases, with no distant metastases, total or nearly total gastrectomy should be performed (4) .
It is widely known that the approach to the treatment of gastric cancer varies significantly between Asian countries (Korea, Japan) and the countries of Western Europe, USA and Canada. Treatment yields significantly better results in the countries of the East. This is not only due to different cancer biology and advancement stage at the time of diagnosis, but also the scope of lymphadenectomy. In Japan, the preferred type is D2 lymphadenectomy, in selected cases D3 lymphadenectomy, while in the USA D1 lymphadenectomy is recommended (5) .
The low five-year survival rate still remains a problematic issue related with gastric cancer, resulting in the search for new solutions, especially neoadjuvant therapy. This type of treatment dates back to the 70s. A phase I clinical trial was conducted in Japan where 62 patients were given an infusion of chemotherapeutic drugs: vinblastine, methotrexate, mitomycin in the gastroepiploic artery 7 days prior to surgery. A higher 3-year survival rate was reported compared to the control group. This treatment resulted particularly beneficial for patients with highly advanced cancer (stage pT4a) (6) . The results of phase II trials were published in 1989. There, a combination of etoposide, adriamycin and cisplatin was administered to 34 patients who had previously undergone laparotomy and their lesion was found to be unresectable; 70% of these patients responded to treatment and 19 patients underwent gastric resection: R0 in 15 patients and R1 in 3 patients (7).
In 2006, the results of the MAGIC trial were published. The trial included 503 patients divided into 2 groups. The first group received chemotherapy based on etoposide, cisplatin and 5-fluorouracil in the perioperative period, while the second group underwent surgery only. The 5-year survival rate in the group that received perioperative chemotherapy was 36.3%, while in the group that received surgical treatment only: 23% (5) .
Despite the growing understanding of the pathophysiological processes in the perioperative period and significant advancements in surgical techniques, operative treatment for gastric cancer remains a challenge for surgeons, especially because the primary procedure of total or nearly total gastrectomy must at times be extended by the resection of other organs. Currently, there is a shift in the surgical approach worldwide from extensive resections towards less invasive strategies involving more selective lymphadenectomy (8, 9, 10) . The scope of surgical interventions is currently strongly debated, especially in terms of the scope of lymphadenectomy and simultaneously performed splenectomy as well the influence of these on the course of the postoperative period. According to some researchers, the removal of a larger number of lymph nodes, especially those of group 10 and 11, which is very commonly associated with splenectomy, improves 5-year survival rates. On the other hand, Brady et al. (11) have reported that splenectomy performed simultaneously with gastrectomy has no direct effect on survival but increases perioperative morbidity and therefore should be avoided unless the spleen is in the immediate vicinity of the tumour or is infiltrated by the tumour.
This study aimed to asses the influence of performing splenectomy simultaneously with total or nearly total gastrectomy on postoperative complications.
MATERIAL AND METHODS
For the needs of this study, the full documentation of 258 gastric cancer patients from the years 1988-2013 was analysed and included patients who underwent surgical treatment with the intention to treat: total or nearly total gastrectomy and in some cases partial resection, supplemented by the removal of regional lymph nodes. The group comprised 83 women (32.17%) and 175 men (67.83%). During that period, 602 gastric cancer patients were treated under the supervision of S.G., the first author of this publication. The vast majority of patients were not eligible tive psychosis, urinary tract infection (UTI). A proportion test and chi-square test were used for statistical analysis.
RESULTS
In the analysed group of patients undergoing surgery with the intention to treat, the average age was 59.7 years (27-80) for operated women and 62.4 years (35-85) for men.
Among the group of 258 patients, gastrectomy was performed in 145 cases, subtotal gastrectomy in 89 cases, Ivor-Lewis surgery (resection of the upper part of the stomach and lower 1/3 of the oesophagus with oesophagogastric anastomosis in the chest) in 12 cases, gastrectomy with the resection of 1/3 of the lower oesophagus with oesophago-intestinal anastomosis in the chest in 6 cases and upper gastric resection in 3 cases. In turn, splenectomy was performed in 42 patients (42/258, i.e. 16.3%), in 40 cases with simultaneous total gastrectomy and in 2 cases with Billroth II subtotal gastrectomy. This group included 12 women aged 27-77 years (average age 58.5) and 30 men aged 45-80 years (average age 63.7).
Among the group of 258 patients, perioperative complications were observed in a total of 108 patients, i.e. 41.86%.
Death in the perioperative period was observed in 14 (5.4%) patients: 9 patients (aged 76, 74, 67, 74, 78, 78, 52, 64, 82 years) died due to cardiovascular complications, 2 patients (aged 69 and 67 years) died due to diffuse peritonitis caused by duodenal ulcer perforation and duodenal stump dehiscence), 1 patient died due to respiratory failure caused by oesophagointestinal anastomosis dehiscence in the chest, 1 patient died due to oesophago-intestinal anastomotic leakage (subphrenic) and diffuse intravascular coagulation (DIC) and 1 patient died due to upper gastrointestinal bleeding. As can be seen, most deaths involved patients above 60 years of age, compromised, especially with cardiovascular diseases.
Within the entire analysed group, major surgical complications were observed in 23 cases (8.91%) and minor surgical complications in 27 cases (10.46%). Major general complications were observed in 37 cases (14.34%) while for resection (due to advanced stage) and underwent exploratory laparotomy or laparoscopy and palliative treatment where needed. The group included some patients who had received preoperative chemotherapy in previous years and were subsequently operated on in other centres.
The abdominal cavity was incised with a midline incision extended below the navel; tumour resectability and the lack of distant metastases was assessed and subsequently total or nearly total gastrectomy was performed with the simultaneous resection of lesser omentum, greater omentum and lymphadenectomy. Thoractomy was additionally performed in 18 cases: 12 patients undergoing Ivor-Lewis resection of the cardia and six patients undergoing gastrectomy with the resection of 1/3 of the lower oesophagus. Patients who underwent simultaneous splenectomy were analysed in particular detail. Splenectomy was performed in 42 cases, in 15 patients simultaneously with the resection of other organs, most commonly the tail of the pancreas (8), but also with the resection of the splenic flexure (4), partial resection of the diaphragm (2), partial resection of the left liver lobe (2) and partial resection of the small intestine (2) .
Postoperative complications reported in the study group were analysed in two subgroups: one without splenectomy and one with splenectomy. A complication was defined as any deviation from the regular postoperative course that occurred within 30 days of surgery. Complications were split into 5 categories: 1) death in the perioperative period (30 days), 2) major surgical complications: oesophagointestinal anastomotic leakage, duodenal stump leakage, upper gastrointestinal bleeding, duodenal ulcer perforation, 3) minor surgical complications: surgical site infection (SSI), fluid collection in the peritoneum, reactions to the IV cannula, leakage following drain removal from the abdominal cavity, prolonged impairment of gastrointestinal motility, 4) major general complications: disseminated intravascular coagulation (DIC), severe cardiac dysrhythmia, acute coronary syndrome, cerebrovascular accident, respiratory failure, renal failure, acute pancreatitis, 5) minor general complications: pyrexia with no apparent reason, atelectasis, pneumonia, bronchitis, pleural effusion, diarrhoea, reac-minor general complications in 75 cases (29.07%). The pathological advancement of gastric cancer (pTN) in the group without splenectomy S(-) and with splenectomy S(+) is shown in tab. 1.
The T4 and N2 traits were observed statistically significantly more often in the S(+) subgroup, which were an indication for splenectomy in previous guidelines concerning gastric cancer, especially when the cancer was located in the upper half of the stomach. The T2 trait was not observed in the S(+) subgroup and the No trait was observed statistically significantly less often.
The characteristics and number of certain complications are presented in tab. 2 and 3.
Complications observed in the assessed group according to the Clavien-Dindo classification (tab. 4) (12) .
Further on in the analysis, two subgroups were identified: I: where splenectomy was performed S(+) and II: where splenectomy was not performed S(-). The occurrence of complications, both surgical (major and minor) and general (major and minor) and deaths in the perioperative period was compared for both subgroups.
With regard to major surgical complications, no statistically significant differences were found in their occurrence in both subgroups (p=0.9031), including the most severe complication: oesophago-intestinal anastomotic leakage (p=0.1579). Similarly, no statistically significant differences were found in the occurrence of minor surgical complications in both subgroups (p=0.4757), both with regard to the most commonly observed complication: prolonged leakage from abdominal drains (p=0.7694) and in the case of surgical site infections (SSI) (p=0.8486). Moreover, no statistically significant differences were found in the occurrence of major general complications in both subgroups (p=0.1096). In this category of complications, respiratory insufficiency was relatively common, significantly more common in the subgroup with splenectomy (p=0.0025). However, it is worth bearing in mind that in some cases additional procedures besides splenectomy were performed, such as the resection of the tail of the pancreas.
Minor general complications constituted the majority in both subgroups both in numerical and percentage terms and were found to occur statistically significantly more often in the group with splenectomy (p=0.0001).
As mentioned above, perioperative mortality in the entire group was 5.4% (14/258), but accounted for 2.4% (1/42) in the subgroup with splenectomy and 6% (13/216) in the subgroup without splenectomy. However, this difference was not statistically significant (p=0.5682).
DISCUSSION
Gastric cancer still remains an important therapeutic issue. Despite a decrease in inci- Ito et al. (13) report that splenectomy should not be performed as a preventive measure simultaneously with lymphadenectomy in patients with pT1-T2 tumours, and the procedure does not improve long-term survival rates in patients with pT3-T4 tumours. This is associated with the fact that none of the patients with gastric cancer located in the upper third part of the stomach had metastases to the lymph nodes of the spleen cavity in the pT1-T2 stage. On the other hand, patients with pT3-T4 tumours from the group where splenectomy was performed had shorter average survival rates. The authors (13) have proposed a few hypotheses to explain this phenomenon. First, disease progression was more advanced in the group where splenectomy was performed; second, the incidence of metastases to the lymph nodes of the spleen cavity was low, therefore patients did not benefit from splenectomy; third, lymphadenectomy does not solve the problem of other routes of tumour spreading, such as via blood vessels and intraperitoneal tumour spread. Nashimoto et al. (14) have also reported that although splenectomy is a safe procedure, it increases the risk of perioperative morbidity when performed during gastrectomy. The difference did not bear statistical relevance with regard to non-surgical complications; surgical complications occurred more frequently but without statistical relevance, except the development of pancreatic fistula (p=0.0008).
Similar results have been reported by Papenfuss et al. (15). These authors believe that perioperative morbidity increases significantly in patients undergoing gastrectomy simultaneously with splenectomy. In a study on a group of 132 patients, Głuszek and Kot (16) found more general complications in the subgroup of patients undergoing splenectomy than in patients undergoing gastrectomy alone. Different conclusions in terms of the assessed risk of complications following simultaneously performed splenectomy and gastrectomy may be drawn from the abovementioned papers (13) (14) (15) (16) . Multi-aspect analysis of the results of these studies brings to the conclusion that splenectomy is a risk factor that increases the frequency of postoperative complications to a varying degree.
Other studies have also found that there is no need for extended resection of lymph nodes and thereby splenectomy or splenectomy with partial pancreatectomy, because these interventions do not improve survival rates but increase the risk of postoperative complications (8, 9) .
However, Yang et al. (17) conducted a metaanalysis with 466 patients of whom 231 underwent splenectomy and found no statistically relevant differences in perioperative morbidity and mortality (15). Stojcev et al. report similar findings (10) . The authors share the view that splenectomy performed simultaneously with gastrectomy in the treatment of gastric cancer has no statistically significant influence on short-term morbidity and mortality (10) .
Postoperative complication categories are identified only in some of the papers mentioned above (10, 14) . The authors of this paper believe that complications such as oesophagointestinal anastomotic leakage should not be viewed as equivalent to impaired gastrointestinal motility or prolonged leakage from drains. The importance of respiratory failure or acute coronary syndrome differs from that of pleural effusion. Complications referred to as "minor" in this paper are not insignificant and may develop into "major" complications, becoming a serious clinical problem.
The authors of the Polish Consensus on Treatment of Gastric Cancer (18) do not recommend routine performance of splenectomy. Although study results concerning splenectomy as a supplementary procedure to gastrectomy and lymphadenectomy are varied, one conclusion may be drawn from all analyses, namely that in some cases the procedure can increase the risk of postoperative complications (surgical and general) even if this does not bear statistical relevance (6, 9, 20) .
CONCLUSIONS
Splenectomy performed simultaneously with gastrectomy for gastric cancer increases the risk of general complications. However, it does not increase the risk of severe surgical complications, such as oesophago-intestinal anastomotic leakage and does not increase the risk of death.
